Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function.
Fortitude on the Frontiers of Science
In this 2-part series, Cytokinetics & National Geographic Explorer Dr. Mireya Mayor investigate how to push the boundaries of medical research farther and faster.
Cardiovascular diseases are the leading cause of death in the U.S. and in many places around the world. We’re focused on finding potential treatments for people with heart failure and hypertrophic cardiomyopathy.
Neuromuscular diseases can cause loss of muscle function, muscle weakness and fatigue. Our goal is develop potential therapies for people with amyotrophic lateral sclerosis and spinal muscular atrophy.
- Cytokinetics Releases Inaugural Corporate Responsibility Report
- Cytokinetics to Participate in Upcoming Investor Conferences
- Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session
Cytokinetics Corporate Presentation
We have robust pipeline of small molecule muscle activators and inhibitors, including omecamtiv mecarbil, reldesemtiv, aficamten, and CK-136.
We seek exceptional individuals to join us in our mission to develop the next generation of novel small molecule muscle-directed potential medicines.